[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3104854T3 - Stabilizatory komórek tucznych do leczenia choroby płuc - Google Patents

Stabilizatory komórek tucznych do leczenia choroby płuc

Info

Publication number
PL3104854T3
PL3104854T3 PL15746049T PL15746049T PL3104854T3 PL 3104854 T3 PL3104854 T3 PL 3104854T3 PL 15746049 T PL15746049 T PL 15746049T PL 15746049 T PL15746049 T PL 15746049T PL 3104854 T3 PL3104854 T3 PL 3104854T3
Authority
PL
Poland
Prior art keywords
lung disease
mast cell
disease treatment
cell stabilizers
stabilizers
Prior art date
Application number
PL15746049T
Other languages
English (en)
Inventor
William Gerhart
Manfred Keller
Ahmet Tutuncu
Pravin Soni
Original Assignee
Respivant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivant Sciences Gmbh filed Critical Respivant Sciences Gmbh
Publication of PL3104854T3 publication Critical patent/PL3104854T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
PL15746049T 2014-02-10 2015-02-09 Stabilizatory komórek tucznych do leczenia choroby płuc PL3104854T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461937928P 2014-02-10 2014-02-10
US201461971709P 2014-03-28 2014-03-28
US201461978711P 2014-04-11 2014-04-11
US201562105453P 2015-01-20 2015-01-20
EP15746049.4A EP3104854B1 (en) 2014-02-10 2015-02-09 Mast cell stabilizers for lung disease treatment
PCT/US2015/015033 WO2015120392A1 (en) 2014-02-10 2015-02-09 Mast cell stabilizers for lung disease treatment

Publications (1)

Publication Number Publication Date
PL3104854T3 true PL3104854T3 (pl) 2020-11-30

Family

ID=53773988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15746049T PL3104854T3 (pl) 2014-02-10 2015-02-09 Stabilizatory komórek tucznych do leczenia choroby płuc

Country Status (13)

Country Link
US (4) US20150224078A1 (pl)
EP (2) EP3725311A1 (pl)
JP (2) JP2017505348A (pl)
CN (1) CN106535889A (pl)
AU (2) AU2015213681B2 (pl)
CA (1) CA2938996A1 (pl)
DK (1) DK3104854T3 (pl)
ES (1) ES2792682T3 (pl)
HU (1) HUE049323T2 (pl)
PL (1) PL3104854T3 (pl)
PT (1) PT3104854T (pl)
SI (1) SI3104854T1 (pl)
WO (1) WO2015120392A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015120392A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
HUE047319T2 (hu) 2014-02-10 2020-04-28 Respivant Sciences Gmbh Hízósejt-stabilizátorral történõ kezelés szisztémás rendellenességekhez
WO2017011729A1 (en) * 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3506894B1 (en) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3506893A4 (en) * 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
WO2020010049A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation POWDERED FORMULATIONS OF CROMOLYN SODIUM AND α-LACTOSE
CN110833538A (zh) * 2018-08-17 2020-02-25 北京盈科瑞创新药物研究有限公司 一种吸入用色甘酸钠溶液制剂及其制备方法和应用
WO2020055687A1 (en) * 2018-09-10 2020-03-19 Cornell University Methods for treating pulmonary hypertension
MX2021013496A (es) * 2019-05-07 2022-01-06 Advita Lifescience Gmbh Peptido intestinal vasoactivo (vip) para usar en el tratamiento de la neumonitis inducida por farmacos.
US11857531B2 (en) 2020-08-05 2024-01-02 Northwestern University Combination mast cell inhibition for treatment of BPH/LUTS

Family Cites Families (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US118991A (en) * 1871-09-12 Improvement in tables and stands
US1039867A (en) 1910-03-25 1912-10-01 Reversible Gas Engine Company Ignition-timer.
US1039107A (en) 1911-08-16 1912-09-24 Dean Electric Co Governing device.
US3686412A (en) 1965-03-25 1972-08-22 Colin Fitzmaurice Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions
US3777033A (en) 1965-03-25 1973-12-04 Fisons Pharmaceuticals Ltd Bis-chromonyl pharmaceutical composi-tion and methods
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3686320A (en) 1965-03-25 1972-08-22 Fisons Pharmaceuticals Ltd Bis-phenoxy compounds
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3720690A (en) 1970-04-10 1973-03-13 Fisons Pharmaceuticals Ltd Pharmaceutically active bis-carboxychromone compounds
US3683320A (en) 1970-05-08 1972-08-08 Bunker Ramo Coaxial cable connectors
CA958714A (en) 1970-09-03 1974-12-03 Peter B. Johnson Bis-chromone derivatives
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US4152448A (en) 1972-02-15 1979-05-01 Fisons Limited Method and composition for the treatment of a condition of the gastro intestinal tract
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
HK38179A (en) 1973-12-19 1979-06-22 Fisons Ltd Topical compositions
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4067992A (en) 1975-09-10 1978-01-10 Fisons Limited Method of treating a psychiatric condition
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4189571A (en) 1978-02-07 1980-02-19 Fisons Limited Esters of cromoglycates
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4268519A (en) 1979-06-05 1981-05-19 Fisons Limited Method of treating otitis media
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
EP0084898B1 (en) 1982-01-22 1986-09-03 FISONS plc Liposome and sodium cromoglycate compositions, and methods for their preparation
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4996296A (en) 1983-07-27 1991-02-26 Yeda Research & Development Co., Ltd. Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
US4683135A (en) 1983-07-27 1987-07-28 Yeda Research And Development Co., Ltd. DSCG binding protein and process for preparing same
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
US4634699A (en) 1983-11-30 1987-01-06 Burroughs Wellcome Co. Branched chain phenothiazine
GB8332450D0 (en) 1983-12-06 1984-01-11 Fisons Plc Method of treatment
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB2167300B (en) 1984-11-23 1988-11-23 Fisons Plc Formulations
JPH0662601B2 (ja) 1985-08-16 1994-08-17 京都薬品工業株式会社 クロモグリク酸誘導体および抗アレルギ−剤
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
DE3879811T2 (de) 1987-08-25 1993-10-07 Kuebler Gmbh Dr Pharmazeutische Zusammensetzung und ihre Verwendung.
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
EP0413583A3 (en) 1989-08-18 1991-07-17 Dey Laboratories; Inc. Clear, stable cromolyn formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
US5753208A (en) 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
EP1875917A3 (en) 1990-12-05 2012-11-28 The General Hospital Corporation Use of NO for the treatment or prevention of reversible pulmonary vasoconstriction
DE59107894D1 (de) 1991-03-21 1996-07-11 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
EP0540774B1 (de) 1991-11-07 1995-05-03 PAUL RITZAU PARI-WERK GmbH Flüssigkeitszerstäubervorrichtung
ATE155695T1 (de) 1991-11-07 1997-08-15 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur anwendung in geräten für die inhalationstherapie
US5618842A (en) 1991-12-31 1997-04-08 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
GB9214390D0 (en) 1992-07-07 1992-08-19 Fisons Plc Formulations
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
GB9317752D0 (en) 1993-08-26 1993-10-13 Fisons Plc New pharmaceutical use
EP0663241B1 (de) 1993-12-17 1998-07-15 PARI GmbH Spezialisten für effektive Inhalation Zerstäuberdüse
US5508451A (en) 1994-07-07 1996-04-16 Hoechst Celanese Corporation Process for the preparation of dialkali metal cromoglycates
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5552436A (en) 1995-04-03 1996-09-03 Ascent Pharmaceuticals, Inc. Process for treating hemangioma
US5576346A (en) 1995-04-03 1996-11-19 Ascent Pharmaceuticals, Inc. Process for treating uremic pruritus
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US6004949A (en) 1995-12-27 1999-12-21 Showa Yakuhin Kako Co., Ltd. Aqueous composition containing cromoglycic acid
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997038693A1 (en) 1996-04-18 1997-10-23 Alcon Laboratories, Inc. Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
AU7833698A (en) 1997-06-09 1998-12-30 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5952353A (en) 1997-09-19 1999-09-14 Auburn University Treating/preventing heart failure via inhibition of mast cell degranulation
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
JP2001517692A (ja) 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
AU748867B2 (en) 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
DE59904648D1 (de) * 1998-08-04 2003-04-24 Jago Res Ag Muttenz Medizinische aerosolformulierungen
IL140930A0 (en) 1998-08-07 2002-02-10 Emisphere Tech Inc Compounds and compositions for delivering active agents
US6138973A (en) 1998-09-15 2000-10-31 Brunswick Corporation Adjustable seat pedestal
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
JP2002532520A (ja) 1998-12-22 2002-10-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 気道病治療および気道用薬剤送達のための化合物および方法
EP1146860A4 (en) 1999-01-08 2002-07-03 Emisphere Tech Inc POLYMER DRUG DELIVERY SYSTEMS AND COMPOUNDS
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
AU4979700A (en) 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
DE60017152D1 (de) 1999-08-25 2005-02-03 Advanced Inhalation Res Inc Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US9755314B2 (en) 2001-10-16 2017-09-05 Fractus S.A. Loaded antenna
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
JP5196701B2 (ja) 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6596284B1 (en) 2002-04-30 2003-07-22 Thomas E. Fleming Treating eczema with a combination of isotonic saline ocean® and nasal mast cell stabilizers
EP1542721A4 (en) 2002-06-14 2007-05-02 Centocor Inc MODIFIED "S" ANTIBODIES
EP1539792A4 (en) 2002-06-27 2005-12-21 Centocor Inc CNGH0005 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2490533A1 (en) 2002-06-27 2004-01-08 Centocor, Inc. Cngh0004 polypeptides, antibodies, compositions, methods and uses
AU2003272450A1 (en) 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
AU2004274390A1 (en) 2003-03-28 2005-03-31 Jacqueline M. Benson Anti-amyloid antibodies, compositions, methods and uses
WO2004091519A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
WO2004101750A2 (en) 2003-05-09 2004-11-25 Centocor, Inc. IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US20050026880A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20050209141A1 (en) 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
EP1684703A4 (en) 2003-11-05 2008-10-01 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH MCP-1
US20060078558A1 (en) 2003-11-12 2006-04-13 Whitsett Jeffrey A Diagnosis, prognosis and treatment of pulmonary diseases
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20050191246A1 (en) 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
WO2005063732A1 (en) 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma
IL160936A0 (en) 2004-02-05 2004-08-31 Scott A Cordray Nasal spray and wash
CA2557724A1 (en) 2004-02-27 2005-10-06 Centocor, Inc. Methods and compositions for treating il-13 related pathologies
NZ551241A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Aryl ketone compounds and compositions for delivering active agents
WO2005115468A1 (ja) 2004-05-26 2005-12-08 Reverse Proteomics Research Institute Co., Ltd. 新規創薬ターゲットならびにこれに作用する医薬
US20060069124A1 (en) 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
WO2006039470A2 (en) 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
CN101175479A (zh) 2005-03-16 2008-05-07 霍尼韦尔国际公司 药物递送制剂、装置和方法
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
AU2012238334A1 (en) 2005-06-30 2012-11-01 Abbvie Inc. IL-12/p40 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
US7566743B2 (en) 2005-11-18 2009-07-28 Mark Glazman System and method for medical treatment
DK1962869T3 (da) 2005-12-21 2013-06-24 Solaeromed Inc Behandling af luftvejssygdomme
PL2548577T3 (pl) 2005-12-29 2017-08-31 Janssen Biotech, Inc Ludzkie przeciwciała anty-il-23 , kompozycje, sposoby i zastosowania
DE102006001113B3 (de) 2006-01-09 2007-06-28 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
BRPI0707641A2 (pt) 2006-02-10 2011-05-10 Pari Pharma Gmbh antibiàticos nebulizados para terapia de inalaÇço
EP2001881A2 (en) 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
US20080035141A1 (en) 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
US20100028351A1 (en) 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
GB0621707D0 (en) 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
EP2091551B1 (en) 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
CN101616583A (zh) 2007-02-08 2009-12-30 爱密斯菲尔科技公司 苯烷基羧酸输送剂
US20080214491A1 (en) 2007-03-02 2008-09-04 Logsdon Craig D Methods of Inhibiting the Interaction Between S100 and the Receptor for Advanced Glycation End-Products
US8252807B2 (en) 2007-03-02 2012-08-28 Board Of Regents, The University Of Texas System Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
US7897776B2 (en) 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
US8445435B2 (en) 2007-09-28 2013-05-21 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
CN102762220A (zh) 2007-10-15 2012-10-31 森托科尔奥索生物科技公司 人抗淀粉样蛋白抗体、组合物、方法和用途发明背景
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
WO2009061895A2 (en) 2007-11-06 2009-05-14 3M Innovative Properties Company Medicinal inhalation devices and components thereof
NZ586105A (en) 2007-12-20 2012-09-28 Astrazeneca Ab Dispenser and method for entraining powder in an airflow by creating eddies over recessed powder containing cavity within flat upstrean and downstream surfaces
WO2009103067A2 (en) 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
WO2009131695A1 (en) 2008-04-25 2009-10-29 Nektar Therapeutics Oligomer-bis-chromonyl compound conjugates
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2010006059A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
US20100087455A1 (en) 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
US20110195924A1 (en) 2008-10-08 2011-08-11 Logsdon Craig D Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products
WO2010057214A2 (en) 2008-11-17 2010-05-20 Wayne State University Nanoparticles and porous particles and methods of making the same
WO2010065547A1 (en) 2008-12-01 2010-06-10 Map Pharmaceuticals, Inc. Inhalation delivery methods and devices
CA2745271A1 (en) 2008-12-04 2010-06-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CA2749966A1 (en) 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP5731406B2 (ja) 2009-01-29 2015-06-10 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体、クロモリン誘導体を用いた治療方法及び造影方法
KR101579771B1 (ko) 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
US8470805B2 (en) 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
US20110263827A1 (en) 2009-05-01 2011-10-27 Abbott Laboratories Dual Variable Domain Immunnoglobulins and Uses Thereof
ES2457442T3 (es) * 2009-05-08 2014-04-25 Pari Pharma Gmbh Formulaciones farmacéuticas concentradas estabilizadoras de los mastocitos
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2488201A4 (en) 2009-10-15 2013-12-25 Abbvie Inc IL-1 BINDING PROTEINS
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
AU2015200579A1 (en) 2010-04-07 2015-02-26 Abbvie Inc. TNF-alpha binding proteins
JP2013523153A (ja) 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
AU2016222339B2 (en) 2010-05-14 2017-11-23 Abbvie Inc. IL-1 binding proteins
KR101539684B1 (ko) 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
US8586044B2 (en) 2010-05-28 2013-11-19 Northwestern University Treatment of chronic pelvic pain syndrome
US9592220B2 (en) 2010-06-17 2017-03-14 Aradigm Corporation Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
WO2012010877A2 (en) 2010-07-21 2012-01-26 Astrazeneca Ab New device
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20120076859A1 (en) 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
AU2011323521A1 (en) 2010-11-02 2013-06-20 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
EP2658538A2 (en) * 2010-12-30 2013-11-06 M.D. Ziv Harish Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables
GB201110058D0 (en) 2011-06-15 2011-07-27 3M Innovative Properties Co Medicinal inhalation devices, valves and components thereof
GB201304499D0 (en) 2011-09-06 2013-04-24 Verona Pharma Plc Carcainium Salts
US20130195871A1 (en) 2011-12-30 2013-08-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY34556A (es) 2011-12-30 2013-07-31 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
CN104540504A (zh) 2012-01-18 2015-04-22 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
GB2498746A (en) 2012-01-26 2013-07-31 Innovata Biomed Ltd Inhaler which locks when empty
AU2013227351B2 (en) 2012-02-28 2016-06-16 Iceutica Holdings Inc. Inhalable pharmaceutical compositions
US20150018396A1 (en) 2012-03-08 2015-01-15 President And Fellows Of Harvard College Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US10105500B2 (en) 2012-05-09 2018-10-23 Virginia Commonwealth University Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions
BR112014029442A2 (pt) 2012-05-25 2017-06-27 Xlear Inc composições antimucosas à base de xilitol e métodos e composições relacionados
WO2014006631A1 (en) 2012-07-04 2014-01-09 Vijaya Rama Raju MUDUNURI Partitioned pool
US9427534B2 (en) 2012-07-05 2016-08-30 Clement Clarke International Ltd. Drug delivery inhaler devices
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
ES2900342T3 (es) 2012-08-21 2022-03-16 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
AU2013345062B2 (en) 2012-11-16 2018-02-08 Merck Sharp & Dohme Corp. Process for making agglomerates using acoustic mixing technology
WO2014115098A1 (en) 2013-01-26 2014-07-31 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and inflammation
BR112015023557A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligações dual específicas direcionadas contra tnfa
CN105377037A (zh) 2013-05-23 2016-03-02 Az治疗公司 用于递送色甘酸的方法
AU2014308606B2 (en) 2013-08-23 2017-08-03 Afferent Pharmaceuticals Inc. Diaminopyrimidine P2X3 and P2X 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9492408B2 (en) 2013-10-24 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Protection from chemical-induced acute lung injury
GB2522727B (en) 2013-11-26 2017-01-25 Purity Health Pharma Ltd Pulmonary delivery devices
EP2883564A1 (en) 2013-12-16 2015-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3102939A4 (en) 2014-02-05 2018-02-28 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
HUE047319T2 (hu) 2014-02-10 2020-04-28 Respivant Sciences Gmbh Hízósejt-stabilizátorral történõ kezelés szisztémás rendellenességekhez
WO2015120392A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
US20150273119A1 (en) 2014-03-26 2015-10-01 Snu R&Db Foundation Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating
US20150306107A1 (en) 2014-04-24 2015-10-29 Jansfat Biotechnology Co., Ltd. SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
WO2015161510A1 (en) 2014-04-25 2015-10-29 Jansfat Biotechnology Co., Ltd. Saa derivative compound restores enos and inhibits oxidative stress-induced diseases in hypoxia
US20150337315A1 (en) 2014-05-20 2015-11-26 Michael M. Grunstein Compositions and methods targeting signaling by the g protein beta-gamma subunit for the treatment of asthma
DE102014009164A1 (de) 2014-06-03 2015-12-03 Herbalist & Doc Gesundheitsgesellschaft Mbh Silikonölhaltige nasal anzuwendende Formulierungen
ES2873080T3 (es) 2014-06-05 2021-11-03 Transgenion Int Institute For Regenerative Translational Medicine Gmbh Métodos de diagnosticar enfermedad pulmonar obstructiva crónica (EPOC) usando novedosos biomarcadores moleculares
JP6755240B2 (ja) 2014-06-05 2020-09-16 トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
EP3152329A2 (en) 2014-06-05 2017-04-12 Transregion-International Institute For Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
WO2016011254A1 (en) 2014-07-16 2016-01-21 Henry J. Legere Md, Pa Combinations of antihistamines and leukotriene antagonists and methods of use thereof
KR101749414B1 (ko) 2014-09-30 2017-06-21 주식회사 엘지화학 (메트)아크릴레이트 화합물, 이로부터 유도된 반복단위를 포함하는 코폴리머 및 호모폴리머
WO2016064908A1 (en) 2014-10-25 2016-04-28 Sumner Bluffs, Llc. Systems and methods for determining compliance and efficacy of a dosing regimen for a pharmaceutical agent
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017048860A1 (en) 2015-09-14 2017-03-23 Vgsk Technologies, Inc. A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS

Also Published As

Publication number Publication date
AU2020203515A1 (en) 2020-06-18
EP3725311A1 (en) 2020-10-21
HUE049323T2 (hu) 2020-09-28
ES2792682T3 (es) 2020-11-11
SI3104854T1 (sl) 2020-09-30
PT3104854T (pt) 2020-06-26
US10835512B2 (en) 2020-11-17
CN106535889A (zh) 2017-03-22
EP3104854A4 (en) 2017-10-18
US20150224078A1 (en) 2015-08-13
US20190328700A1 (en) 2019-10-31
AU2015213681A1 (en) 2016-08-25
JP2017505348A (ja) 2017-02-16
US20160346246A1 (en) 2016-12-01
EP3104854A1 (en) 2016-12-21
EP3104854B1 (en) 2020-04-08
US20160367520A1 (en) 2016-12-22
WO2015120392A1 (en) 2015-08-13
JP2020023542A (ja) 2020-02-13
DK3104854T3 (da) 2020-05-04
AU2015213681B2 (en) 2020-03-12
CA2938996A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
PL3104854T3 (pl) Stabilizatory komórek tucznych do leczenia choroby płuc
SI3132034T1 (sl) Zdravstveni pripomočki
PL3104853T3 (pl) Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
SG11201605585SA (en) Targeted therapy for small cell lung cancer
PT3094237T (pt) Eletrocardiógrafo
PL3509156T3 (pl) Roztwór elektrolitu
GB201415569D0 (en) Therapeutic Compounds
HK1215864A1 (zh) 用於埋線療法的套管
GB201407322D0 (en) Gene therapy
GB201410216D0 (en) Therapeutic
GB201522223D0 (en) Therapeutic T cells
GB201510637D0 (en) Therapeutic
GB201416273D0 (en) Therapeutic compounds
PL3023085T3 (pl) Trumna
GB201517329D0 (en) Diabetes gene therapy
GB201414542D0 (en) Novel therapy
TWM490296U (en) Medical auxiliary lighting
TWI860574B (zh) 細胞傷害誘導治療劑
TWI860447B (zh) 細胞傷害誘導治療劑
GB201517420D0 (en) Improvements to bedpans
GB201418508D0 (en) Therapeutic
GB201413719D0 (en) Therapeutic
GB201410832D0 (en) Therapeutic
GB201410334D0 (en) Therapeutic
GB201411570D0 (en) Therapy